

Table 3. Clinical characteristics of subjects.

	PD (n=108)	CBS (n=13)	MSA (n=15) -P (n=12), -C (n=3)	PSP (n=17)	VP (n=7)	ET (n=13)	DIP (n=7)	HS (n=39)
Sex, n (M/F)	56/52	1/12	7/8	11/6	4/3	8/5	3/4	21/18
Age yrs., ave. (range)	72.0 (44-88)	75.8 (62-86)	69.0 (58-86)	73.9 (61-80)	77.9 (68-87)	60.9 (27-82)	72.3 (62-80)	73.1 (62-85)
Disease duration, month, ave. $\pm$ SD (range)	41.0 $\pm$ 43.0 (1-204)	45.5 $\pm$ 26.6 (12-108)	28.0 $\pm$ 20.0 (6-60)	31.1 $\pm$ 21.9 (6-96)	41.0 $\pm$ 47.1 (4-144)	126 $\pm$ 187 (3-600)	8.7 $\pm$ 7.3 (3-24)	NA
Dysosmia, n (+/-/not examined)	11/40/57	0/1/12	0/10/5	0/9/8	0/2/5	0/2/11	1/0/6	NA

The ANOVA comparison of disease duration across groups indicates no significant difference (F value = 2.59; P value = 0.062). PD = Parkinson's disease; CBS = corticobasal syndrome; MSA = multiple system atrophy; PSP = progressive supranuclear palsy; VP = vascular Parkinsonism; ET = essential tremor; DIP = drug-induced parkinsonism; HS = healthy subject; M = male; F = female; ave. = average; SD = standard deviation; NA= not analyzed.